CN105452265B - 用于治疗肿瘤性疾病尤其具有高her2蛋白水平的肿瘤性疾病的他莫昔芬衍生物 - Google Patents

用于治疗肿瘤性疾病尤其具有高her2蛋白水平的肿瘤性疾病的他莫昔芬衍生物 Download PDF

Info

Publication number
CN105452265B
CN105452265B CN201480033316.9A CN201480033316A CN105452265B CN 105452265 B CN105452265 B CN 105452265B CN 201480033316 A CN201480033316 A CN 201480033316A CN 105452265 B CN105452265 B CN 105452265B
Authority
CN
China
Prior art keywords
general formula
tamoxifen
derivatives
mitochondria
isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480033316.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105452265A (zh
Inventor
伊里·纽齐尔
J·什图尔萨
L·维尔纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUZIL JIRI
Smart Brain sro
Springboard Investment Co
INSTITUTE OF BIOTECHNOLOGY
Original Assignee
Kkcg Co ltd
Smart Brain sro
INSTITUTE OF BIOTECHNOLOGY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105452265(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ2013308A3/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by Kkcg Co ltd, Smart Brain sro, INSTITUTE OF BIOTECHNOLOGY filed Critical Kkcg Co ltd
Publication of CN105452265A publication Critical patent/CN105452265A/zh
Application granted granted Critical
Publication of CN105452265B publication Critical patent/CN105452265B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
CN201480033316.9A 2013-04-24 2014-04-07 用于治疗肿瘤性疾病尤其具有高her2蛋白水平的肿瘤性疾病的他莫昔芬衍生物 Expired - Fee Related CN105452265B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CZPV2013-308 2013-04-24
CZ2013-308A CZ2013308A3 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZPV2014-66 2014-01-29
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
PCT/CZ2014/000035 WO2014173374A1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Publications (2)

Publication Number Publication Date
CN105452265A CN105452265A (zh) 2016-03-30
CN105452265B true CN105452265B (zh) 2017-05-10

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480033316.9A Expired - Fee Related CN105452265B (zh) 2013-04-24 2014-04-07 用于治疗肿瘤性疾病尤其具有高her2蛋白水平的肿瘤性疾病的他莫昔芬衍生物

Country Status (21)

Country Link
US (1) US9896466B2 (enExample)
EP (1) EP2989110B1 (enExample)
JP (1) JP6375091B2 (enExample)
KR (1) KR101764991B1 (enExample)
CN (1) CN105452265B (enExample)
AU (1) AU2014256546B2 (enExample)
CA (1) CA2909994C (enExample)
CY (1) CY1120821T1 (enExample)
DK (1) DK2989110T3 (enExample)
EA (1) EA029881B1 (enExample)
ES (1) ES2699099T3 (enExample)
GE (1) GEP20186868B (enExample)
HR (1) HRP20181872T1 (enExample)
HU (1) HUE042239T2 (enExample)
MD (1) MD4626C1 (enExample)
NZ (1) NZ713589A (enExample)
PL (1) PL2989110T3 (enExample)
PT (1) PT2989110T (enExample)
SI (1) SI2989110T1 (enExample)
UA (1) UA116469C2 (enExample)
WO (1) WO2014173374A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548318B2 (en) * 2015-07-03 2020-02-04 Bayer Cropscience Aktiengesellschaft N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide derivatives with herbicidal action
WO2017005564A1 (de) * 2015-07-03 2017-01-12 Bayer Cropscience Aktiengesellschaft Herbizid wirksame n-(1,3,4-oxadiazol-2-yl)arylcarboxamid-derivate
WO2018013559A1 (en) * 2016-07-12 2018-01-18 Accutar Biotechnology Inc. Novel compounds and uses thereof
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3063717C (en) 2017-05-19 2021-08-24 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
BR112020008022A2 (pt) 2017-10-24 2020-10-27 Lunella Biotech, Inc. mitoflavoscinas: o direcionamento de enzimas contendo flavina elimina as células-tronco de câncer (cscs) por meio da inibição da respiração mitocondrial
US10980821B2 (en) 2017-11-24 2021-04-20 Lunella Biotech, Inc. Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
CA3083487A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019113210A1 (en) 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
WO2019126179A1 (en) 2017-12-20 2019-06-27 Lunella Biotech, Inc. Targeting mitochondrial fission through mdivi-1 derivatives
US20220211728A1 (en) * 2019-04-16 2022-07-07 Lunella Biotech, Inc. Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006068A1 (en) * 1990-10-01 1992-04-16 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
IL173807A (en) * 2003-08-22 2014-02-27 Antipodean Pharmaceuticals Inc Antioxidant amphiphilic compounds, histoquinone history and pharmaceutical preparations containing them
JP2008506667A (ja) * 2004-07-13 2008-03-06 オリディス・ビオメド・フォルシュングス−ウント・エントヴィックルングス・ゲーエムベーハー 肝疾患及び上皮性癌の治療におけるミトコンドリアを標的とした酸化防止剤
JP5616798B2 (ja) * 2008-03-14 2014-10-29 スティーブン・ジョン・ラルフＳｔｅｐｈｅｎ Ｊｏｈｎ ＲＡＬＰＨ ミトコンドリア由来の抗ガン化合物
CA2756820A1 (en) * 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006068A1 (en) * 1990-10-01 1992-04-16 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Delivery of bioactive molecules to mitochondria in vivo;Robin A. J. Smith，et al.;《PNAS》;20030429;第100卷(第9期);5407-5412 *
Tamoxifen and Estradiol Interact with the Flavin Mononucleotide Site of Complex I Leading to Mitochondrial Failure;Paula I. Moreira，et al.;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20060112;第281卷(第15期);10143-10152 *

Also Published As

Publication number Publication date
EP2989110B1 (en) 2018-08-08
EA201591918A1 (ru) 2016-02-29
CA2909994C (en) 2018-06-26
WO2014173374A1 (en) 2014-10-30
MD4626C1 (ro) 2019-11-30
PL2989110T3 (pl) 2019-03-29
HK1216317A1 (zh) 2016-11-04
HRP20181872T1 (hr) 2019-02-08
EP2989110A1 (en) 2016-03-02
CA2909994A1 (en) 2014-10-30
NZ713589A (en) 2017-12-22
JP2016522179A (ja) 2016-07-28
MD20150117A2 (ro) 2016-08-31
JP6375091B2 (ja) 2018-08-15
KR101764991B1 (ko) 2017-08-10
HUE042239T2 (hu) 2019-06-28
MD4626B1 (ro) 2019-04-30
ES2699099T3 (es) 2019-02-07
AU2014256546B2 (en) 2017-03-30
UA116469C2 (uk) 2018-03-26
CN105452265A (zh) 2016-03-30
EA029881B1 (ru) 2018-05-31
CY1120821T1 (el) 2019-12-11
PT2989110T (pt) 2018-11-15
US20160075726A1 (en) 2016-03-17
US9896466B2 (en) 2018-02-20
GEP20186868B (en) 2018-06-25
KR20150144756A (ko) 2015-12-28
SI2989110T1 (sl) 2019-01-31
AU2014256546A1 (en) 2015-11-12
DK2989110T3 (en) 2018-12-03

Similar Documents

Publication Publication Date Title
CN105452265B (zh) 用于治疗肿瘤性疾病尤其具有高her2蛋白水平的肿瘤性疾病的他莫昔芬衍生物
Burmaoglu et al. Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents
Kurzwernhart et al. Structure–activity relationships of targeted RuII (η6-p-Cymene) anticancer complexes with flavonol-derived ligands
Snegur et al. Ferrocenylalkyl azoles: bioactivity, synthesis, structure
Huang et al. Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt (IV) moiety with a unique mode of action
Panchangam et al. Antitumor effects of Ir (III)-2 H-indazole complexes for triple negative breast cancer
Štarha et al. Platinum (II) iodido complexes of 7-azaindoles with significant antiproliferative effects: an old story revisited with unexpected outcomes
Würtenberger et al. Synthesis and in vitro pharmacological behavior of platinum (II) complexes containing 1, 2-diamino-1-(4-fluorophenyl)-2-alkanol ligands
Ribeiro et al. Ruthenium (II) phosphine/mercapto complexes: their in vitro cytotoxicity evaluation and actions as inhibitors of topoisomerase and proteasome acting as possible triggers of cell death induction
Singh et al. A family of silatrane‐armed triazole‐encapped salicylaldehyde‐derived Schiff bases: Synthesis, spectral analysis, and antimicrobial and quantum chemical evaluation
Yuan et al. Discovery of Arene Ruthenium (II) Complexes as Potential VEGF Inhibitors for Glioblastoma Metastasis Suppression
Alexander et al. Dinuclear platinum (II) complexes of imidazophenanthroline-based bridging ligands as potential anticancer agents: synthesis, characterization, and in vitro cytotoxicity studies
Liu et al. Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl) cyclobutane-1, 1-Dicarboxylate as a leaving ligand
EP2924044A1 (en) Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
WO2021212691A1 (zh) 一种线粒体靶向化合物及其制备方法和应用
CA3045365C (en) Compounds for treatment of senescence-related disorders
CN102627685A (zh) 一氧化氮供体型谷胱甘肽类化合物、其制备方法及医药用途
CN110156822A (zh) 一种萘酚-苯硼酸类化合物及其制备方法和用途
CN103214422A (zh) 一类新型取代胺基咪唑酮衍生物的制备方法及抗癌作用
CN108727451B (zh) 新的磷化烃金化合物及其制备方法和应用
HK1216317B (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
CZ304553B6 (cs) Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZ305571B6 (cs) Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
BR112020015745A2 (pt) Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina
BR102020013240A2 (pt) Ligantes binucleantes fenólicos, compostos metálicos binucleares, composição médico-veterinária, processos de síntese de ligantes binucleantes, processo de síntese de compostos binucleares, método de tratamento de neoplasias e doenças fúngicas e uso

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Prague

Applicant after: SMART BRAIN S.R.O.

Applicant after: Institute of Biotechnology

Applicant after: NEUZIL JIRI

Applicant after: KKCG Limited by Share Ltd.

Address before: Prague

Applicant before: SMART BRAIN S.R.O.

Applicant before: Institute of Biotechnology

Applicant before: NEUZIL JIRI

Applicant before: KKCG SE

COR Change of bibliographic data
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1216317

Country of ref document: HK

CB02 Change of applicant information

Address after: Prague

Applicant after: SMART BRAIN S.R.O.

Applicant after: Institute of Biotechnology

Applicant after: NEUZIL JIRI

Applicant after: KKCG CO.,LTD.

Address before: Prague

Applicant before: SMART BRAIN S.R.O.

Applicant before: Institute of Biotechnology

Applicant before: NEUZIL JIRI

Applicant before: KKCG Limited by Share Ltd.

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1216317

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210106

Address after: Prague

Patentee after: SMART BRAIN S.R.O.

Patentee after: Institute of Biotechnology

Patentee after: NEUZIL JIRI

Patentee after: Springboard Investment Co.

Address before: Prague

Patentee before: SMART BRAIN S.R.O.

Patentee before: Institute of Biotechnology

Patentee before: NEUZIL JIRI

Patentee before: KKCG CO.,LTD.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170510